Table 3.

Logistic regression analyses investigating the association of PPI use with iron deficiency in 646 renal transplant recipients.

	Iron Deficiency
n = 646	Odds Ratio	95% CI	p
Crude	1.95	1.37–2.77	<0.001
Model 1	1.94	1.36–2.78	<0.001
Model 2	1.57	1.07–2.31	0.02
Model 3	1.57	1.04–2.38	0.03
Model 4	1.56	1.06–2.30	0.03
Model 5	1.57	1.07–2.31	0.02
Model 6	1.43	0.96–2.12	0.08

Model 1: PPI use adjusted for age and sex. Model 2: model 1 + adjustment for eGFR, proteinuria, time since transplantation, history of GI-disorders. Model 3: model 2 + adjustment for lifestyle parameters (BMI, smoking behavior, alcohol use, dietary iron intake). Model 4: model 2 + adjustment for inflammation (hs-CRP). Model 5: model 2 + adjustment for MMF use. Model 6: model 5 + adjustment for other medication use (diuretic use, RAAS-inhibition, antiplatelet therapy, CNI use, and prednisolone use). Abbreviations: CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; RAAS-inhibitors, renin-angiotensin-aldosterone system inhibitors.